Template:BerkiGEM2007 WikiPlaying
From 2007.igem.org
(Difference between revisions)
| Line 128: | Line 128: | ||
#apDiv4 { | #apDiv4 { | ||
position:absolute; | position:absolute; | ||
| - | left: | + | left:303px; |
| - | top: | + | top:92px; |
width:305px; | width:305px; | ||
height:348px; | height:348px; | ||
| Line 144: | Line 144: | ||
#apDiv6 { | #apDiv6 { | ||
position:absolute; | position:absolute; | ||
| - | left: | + | left:358px; |
| - | top: | + | top:-1px; |
width:75px; | width:75px; | ||
height:93px; | height:93px; | ||
| Line 185: | Line 185: | ||
#apDiv11 { | #apDiv11 { | ||
position:absolute; | position:absolute; | ||
| - | left: | + | left:211px; |
| - | top: | + | top:130px; |
width:84px; | width:84px; | ||
height:91px; | height:91px; | ||
| Line 201: | Line 201: | ||
#apDiv13 { | #apDiv13 { | ||
position:absolute; | position:absolute; | ||
| - | left: | + | left:576px; |
| - | top: | + | top:-2px; |
width:68px; | width:68px; | ||
height:75px; | height:75px; | ||
| Line 209: | Line 209: | ||
#apDiv14 { | #apDiv14 { | ||
position:absolute; | position:absolute; | ||
| - | left: | + | left:628px; |
| - | top: | + | top:214px; |
width:88px; | width:88px; | ||
height:125px; | height:125px; | ||
| Line 250: | Line 250: | ||
#apDiv19 { | #apDiv19 { | ||
position:absolute; | position:absolute; | ||
| - | left: | + | left:254px; |
| - | top: | + | top:397px; |
width:86px; | width:86px; | ||
height:105px; | height:105px; | ||
| Line 258: | Line 258: | ||
#apDiv20 { | #apDiv20 { | ||
position:absolute; | position:absolute; | ||
| - | left: | + | left:476px; |
| - | top: | + | top:436px; |
width:114px; | width:114px; | ||
height:101px; | height:101px; | ||
| Line 390: | Line 390: | ||
#apDiv36 { | #apDiv36 { | ||
position:absolute; | position:absolute; | ||
| - | left: | + | left:641px; |
| - | top: | + | top:496px; |
width:183px; | width:183px; | ||
height:52px; | height:52px; | ||
| Line 423: | Line 423: | ||
#apDiv40 { | #apDiv40 { | ||
position:absolute; | position:absolute; | ||
| - | left: | + | left:191px; |
| - | top: | + | top:542px; |
width:433px; | width:433px; | ||
height:26px; | height:26px; | ||
| Line 431: | Line 431: | ||
#apDiv41 { | #apDiv41 { | ||
position:absolute; | position:absolute; | ||
| - | left: | + | left:3px; |
| - | top: | + | top:654px; |
width:950px; | width:950px; | ||
height:160px; | height:160px; | ||
| Line 499: | Line 499: | ||
#apDiv48 { | #apDiv48 { | ||
position:absolute; | position:absolute; | ||
| - | left: | + | left:145px; |
| - | top: | + | top:1px; |
width:96px; | width:96px; | ||
height:72px; | height:72px; | ||
| Line 515: | Line 515: | ||
#apDiv50 { | #apDiv50 { | ||
position:absolute; | position:absolute; | ||
| - | left: | + | left:1px; |
| - | top: | + | top:0px; |
width:136px; | width:136px; | ||
height:531px; | height:531px; | ||
| Line 563: | Line 563: | ||
<div align="center"><span class="style5"><a href="https://2007.igem.org/Berkeley_UC_Hemoglobin">Begin Project Tour</a></span><a href="https://2007.igem.org/Berkeley_UC_Hemoglobin"><img name="UCForwardButton" src="https://static.igem.org/mediawiki/2007/a/a0/F-Blue.gif" width="65" height="50" alt=""></a></div> | <div align="center"><span class="style5"><a href="https://2007.igem.org/Berkeley_UC_Hemoglobin">Begin Project Tour</a></span><a href="https://2007.igem.org/Berkeley_UC_Hemoglobin"><img name="UCForwardButton" src="https://static.igem.org/mediawiki/2007/a/a0/F-Blue.gif" width="65" height="50" alt=""></a></div> | ||
</div> | </div> | ||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
<div id="apDiv40">Best viewed in the <a href="http://www.mozilla.com/en-US/firefox/"><strong>most recent version of firefox</strong></a>, because IE sucks. </div> | <div id="apDiv40">Best viewed in the <a href="http://www.mozilla.com/en-US/firefox/"><strong>most recent version of firefox</strong></a>, because IE sucks. </div> | ||
Revision as of 00:04, 9 October 2007
Best viewed in the most recent version of firefox, because IE sucks.
The global demand and importance for cheap, available, and disease free blood substitutes is undisputed. There are currently no red blood cell substitutes approved for clinical use in the US or the UK, and whole blood is almost always in short supply. Underdeveloped countries that need blood the most simply don’t have the infrastructure to support donation and storage, in addition a sizeable fraction of the population are disease carriers. We are developing an innovative and cheap blood substitute based on engineered E. coli with all the critical properties of human erythrocytes. These include the ability to safely exist in the bloodstream, carry oxygen, and be stored for prolonged periods in a freeze-dried state.
Introduction
Oxygen Transport
Immunity
- Chassis
- msbB Deletion
Antioxidants
- SodC/KatG
Growth Control
- tonB Deletion
- dapD Deletion
